A Phase 2 interventional study of BOTOX® purified neurotoxin complex and Placebo in Platysma Prominence, sponsored by Allergan. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.
Drug: Placebo
Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
Drug: BOTOX® purified neurotoxin complex
Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
Drug: BOTOX® purified neurotoxin complex
BOTOX® superficial intramuscular injections.
Also known as: Botulinum toxin type A purified neurotoxin complex
Placebo injections.
Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS)
The investigator evaluated the participant's platysma prominence severity using a 5-grade scale C-APPS at maximum contraction where 1= minimal, and 5= extreme. Higher values indicate worsening condition. Data is reported for participants who achieved at least a 1-grade improvement rated on the C-APPS. Percentages are rounded off to whole number at the nearest decimal. Cochran-Mantel-Haenszel (CMH) chi-squared test was used for analysis.
Time frame: Day 14
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. Treatment-emergent adverse events are defined as any event that began or worsened in severity on or after the first dose of study drug or any AE that was present before the first dose of study intervention, but increased in severity or became serious after the first dose of study intervention.
Time frame: From the first dose of study drug up to end of study (up to Day 120)
Pulse Rate at Baseline
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline (Day 1)
Change From Baseline in Pulse Rate at Day 7
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 7
Change From Baseline in Pulse Rate at Day 14
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 14
Change From Baseline in Pulse Rate at Day 30
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 30
Change From Baseline in Pulse Rate at Day 60
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 60
Change From Baseline in Pulse Rate at Day 90
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 90
Change From Baseline in Pulse Rate at Day 120
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
Time frame: Baseline; Day 120
Systolic and Diastolic Blood Pressure (BP) at Baseline
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline (Day 1)
Change From Baseline in Systolic and Diastolic BP at Day 7
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 7
Change From Baseline in Systolic and Diastolic BP at Day 14
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 14
Change From Baseline in Systolic and Diastolic BP at Day 30
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 30
Change From Baseline in Systolic and Diastolic BP at Day 60
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 60
Change From Baseline in Systolic and Diastolic BP at Day 90
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 90
Change From Baseline in Systolic and Diastolic BP at Day 120
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
Time frame: Baseline; Day 120
Respiratory Rate at Baseline
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline (Day 1)
Change From Baseline in Respiratory Rate at Day 7
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 7
Change From Baseline in Respiratory Rate at Day 14
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 14
Change From Baseline in Respiratory Rate at Day 30
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 30
Change From Baseline in Respiratory Rate at Day 60
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 60
Change From Baseline in Respiratory Rate at Day 90
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 90
Change From Baseline in Respiratory Rate at Day 120
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
Time frame: Baseline; Day 120
Percentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS)
The participants evaluated their own Platysma Prominence severity using a 5-grade scale where 1= minimal, and 5= extreme. Higher values indicate worsening conditions. Data is reported for participants who achieved at least a 1-grade improvement rated on the P-APPS. Percentages are rounded off to whole number at the nearest decimal. CMH chi-squared test was used for analysis.
Time frame: Day 14
| Milestone | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Started | 57 | 59 | 55 |
| Modified intent-to-treat (mitt) population | 53 | 58 | 53 |
| Safety population | 56 | 59 | 54 |
| Completed | 47 | 50 | 49 |
| Not completed | 10 | 9 | 6 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 |
| Withdrew: Covid-19 related issues | 2 | 4 | 4 |
| Withdrew: Randomized with incorrect c-apps | 1 | 0 | 0 |
The investigator evaluated the participant's platysma prominence severity using a 5-grade scale C-APPS at maximum contraction where 1= minimal, and 5= extreme. Higher values indicate worsening condition. Data is reported for participants who achieved at least a 1-grade improvement rated on the C-APPS. Percentages are rounded off to whole number at the nearest decimal. Cochran-Mantel-Haenszel (CMH) chi-squared test was used for analysis.
| percentage of participants | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS) | 12.0 (3.0 to 21.0) | 77.8 (66.7 to 88.9) | 88.2 (79.4 to 97.1) |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. Treatment-emergent adverse events are defined as any event that began or worsened in severity on or after the first dose of study drug or any AE that was present before the first dose of study intervention, but increased in severity or became serious after the first dose of study intervention.
| Participants | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE) | 13 | 14 | 14 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats per minute (beats/min) | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Pulse Rate at Baseline | 73.0 ± 10.77 | 74.4 ± 9.77 | 73.6 ± 10.66 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 7 | 1.0 ± 8.19 | -0.5 ± 6.76 | 1.2 ± 13.86 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 14 | 0.4 ± 8.76 | -1.4 ± 7.96 | 1.3 ± 10.49 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 30 | 0.1 ± 11.57 | -0.9 ± 7.09 | -0.5 ± 10.22 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 60 | 0.4 ± 11.14 | 0.3 ± 8.24 | -2.1 ± 11.62 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 90 | 1.1 ± 10.58 | -0.9 ± 8.76 | 0.0 ± 9.45 |
Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.
| beats/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Day 120 | 0.5 ± 12.39 | -0.4 ± 9.24 | 0.8 ± 11.77 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| millimeters of mercury (mmHg) | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic Blood Pressure | 116.6 ± 12.62 | 119.7 ± 14.96 | 120.4 ± 13.38 |
| Diastolic Blood Pressure | 77.2 ± 9.11 | 76.6 ± 9.26 | 77.6 ± 8.81 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | 1.2 ± 11.49 | 1.7 ± 13.37 | -2.0 ± 11.14 |
| Diastolic BP | -0.5 ± 6.66 | 0.3 ± 8.43 | 0.2 ± 8.57 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | 0.0 ± 9.29 | 1.9 ± 13.27 | -1.7 ± 10.17 |
| Diastolic BP | -1.0 ± 6.99 | 1.1 ± 8.69 | -0.5 ± 7.41 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | -2.0 ± 9.25 | -0.7 ± 13.71 | -2.8 ± 9.56 |
| Diastolic BP | -1.3 ± 7.46 | 0.6 ± 8.77 | -0.8 ± 9.01 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | -1.2 ± 9.14 | 2.2 ± 14.49 | -2.6 ± 15.00 |
| Diastolic BP | -0.4 ± 6.50 | 1.9 ± 10.03 | -2.4 ± 9.80 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | 1.4 ± 11.40 | -0.3 ± 11.62 | -2.7 ± 11.89 |
| Diastolic BP | -2.4 ± 8.52 | 0.6 ± 7.14 | -3.2 ± 10.18 |
Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.
| mmHg | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Systolic BP | 0.6 ± 12.05 | 0.1 ± 14.11 | -1.3 ± 10.27 |
| Diastolic BP | -0.7 ± 9.92 | -0.4 ± 10.43 | -0.5 ± 9.11 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths per minute (breaths/min) | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Respiratory Rate at Baseline | 15.6 ± 2.53 | 15.5 ± 2.66 | 15.6 ± 2.51 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 7 | -0.1 ± 1.73 | 0.1 ± 1.80 | -0.2 ± 1.65 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 14 | -0.2 ± 1.20 | -0.1 ± 2.05 | 0.0 ± 1.55 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 30 | -0.3 ± 1.70 | 0.5 ± 1.86 | 0.0 ± 1.63 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 60 | -0.2 ± 1.83 | -0.1 ± 1.69 | 0.2 ± 1.83 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 90 | -0.3 ± 1.85 | -0.1 ± 2.00 | -0.2 ± 2.04 |
Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.
| breaths/min | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Change From Baseline in Respiratory Rate at Day 120 | -0.7 ± 1.71 | -0.2 ± 2.09 | -0.3 ± 1.85 |
The participants evaluated their own Platysma Prominence severity using a 5-grade scale where 1= minimal, and 5= extreme. Higher values indicate worsening conditions. Data is reported for participants who achieved at least a 1-grade improvement rated on the P-APPS. Percentages are rounded off to whole number at the nearest decimal. CMH chi-squared test was used for analysis.
| percentage of participants | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| Percentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS) | 18.0 (7.4 to 28.6) | 75.9 (64.5 to 87.3) | 88.2 (79.4 to 97.1) |
Collected over All cause mortality is reported from enrollment to end of study; median time on follow up was 128.0, 127.0 and 129.0 days for placebo, BOTOX low dose and BOTOX high dose, respectively. TEAEs and SAEs were collected from first dose of study drug until 120 days after last dose of study drug; mean duration on study drug was 1 day for placebo, BOTOX low dose and BOTOX high dose, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/57 (0%) | 0/56 (0%) | 10/56 (17.9%) |
| BOTOX® Low Dose | 0/59 (0%) | 2/59 (3.4%) | 6/59 (10.2%) |
| BOTOX® High Dose | 0/55 (0%) | 0/54 (0%) | 8/54 (14.8%) |
| Event | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| THROMBOCYTOSISBlood and lymphatic system disorders | 0/56 | 1/59 | 0/54 |
| APPENDICITISInfections and infestations | 0/56 | 1/59 | 0/54 |
| Event | Placebo | BOTOX® Low Dose | BOTOX® High Dose |
|---|---|---|---|
| MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders | 0/56 | 0/59 | 6/54 |
| INJECTION SITE BRUISINGGeneral disorders | 4/56 | 4/59 | 3/54 |
| INJECTION SITE HAEMORRHAGEGeneral disorders | 3/56 | 2/59 | 1/54 |
| NASOPHARYNGITISInfections and infestations | 3/56 | 0/59 | 1/54 |
mITT population included all randomized participants who had at least 1 post-baseline assessment of the primary efficacy parameter, the C-APPS, as described in the protocol.
| Age, Continuous(years) | Placebo | BOTOX® Low Dose | BOTOX® High Dose | Total |
|---|---|---|---|---|
| Mean | 49.3 ± 9.59 | 51.8 ± 9.16 | 48.6 ± 10.21 | 50.0 ± 9.69 |
| Sex: Female, Male(Participants) | Placebo | BOTOX® Low Dose | BOTOX® High Dose | Total |
|---|---|---|---|---|
| Female | 52 | 54 | 50 | 156 |
| Male | 1 | 4 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | BOTOX® Low Dose | BOTOX® High Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 6 | 17 |
| Not Hispanic or Latino | 48 | 52 | 47 | 147 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | BOTOX® Low Dose | BOTOX® High Dose | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 49 | 56 | 49 | 154 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Apr 2019 to primary completion in Apr 2020, 11 months.
Results were first posted in May 2023, 3 years after primary completion. A results delay was requested in Apr 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A